Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Stronger-than-expected results led Lilly’s leadership to look beyond its current weight-loss franchise, with CEO David Ricks citing retatrutide as a potential next growth driver.
THE APEX TIMES
THE APEX TIMES
CVS Health rallied after reporting a second-quarter earnings beat and lifting its full-year outlook, while also highlighting a partnership with Eli Lilly tied to its weight-loss therapy.
THE APEX TIMES
The healthcare company reported a stronger-than-expected quarter and said it now expects better performance for 2026, sending its shares higher in early trading.
THE APEX TIMES
In its latest quarterly update, Eli Lilly said revenue and net income rose, supported by continued demand for its GLP-1-based therapies used for weight management and related indications.
THE APEX TIMES
The two leading makers of GLP-1-based obesity and diabetes medicines raised their full-year outlooks, indicating that demand has continued to outpace earlier expectations.
THE APEX TIMES
The drugmaker posted second-quarter revenue of $15 billion and adjusted diluted earnings per share of $0.77, saying both figures beat its own forecast levels.
THE APEX TIMES
Shares of Eli Lilly (LLY) jumped more than 5% in premarket trading after the company lifted its annual revenue guidance, citing demand for its weight-loss and diabetes therapies.
THE APEX TIMES
Reported Q2 revenue strength from weight-loss and diabetes drugs helped Eli Lilly beat Wall Street expectations, with Mounjaro sales rising 91% year over year to $9.9 billion and Zepbound reaching $4.9 billion.
THE APEX TIMES
CVS Health reported a second-quarter earnings beat and raised its full-year profit forecast to as much as $8.10 per share, while market coverage also pointed to an Eli Lilly weight-loss drug arrangement as investors looked for demand and affordability outlines in obesity care.
